New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy

AbstractBackground:Obesity is one of the major problems of health policy in different countries. Pharmacological attempts have been made to help affected people without a definitive solution. Some agents – either with peripheral or central effect – are available in the market. On July 2012, the FDA approved two novel preparations for obese patients: (1) topiramate–phentermine – the first one an anticonvulsant and the second one a sympathomimetic amine – and (2) lorcaserin, a 5-HT2CR agonist. Both preparations emerged as new options for weight management.Scope:Based on the complex biology of eating behavior, in this review we discuss the features, mechanisms of action, pharmacokinetics, advantages and possible disadvantages of these new agents.Conclusion:With differences in efficacy (higher for the topiramate–phentermine combination), both preparations are active in reducing appetite and body weight, as well as in improving comorbidities. Additional information will be collected from Phase IV surveillance....